Get the Stockscreener App
60.23
3.10%
1.81
After Hours:
60.34
0.11
+0.18%
Dexcom Inc stock is traded at $60.23, with a volume of 5.45M.
It is up +3.10% in the last 24 hours and down -13.65% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$58.42
Open:
$58.5
24h Volume:
5.45M
Relative Volume:
0.86
Market Cap:
$23.49B
Revenue:
$4.30B
Net Income/Loss:
$571.50M
P/E Ratio:
42.16
EPS:
1.4285
Net Cash Flow:
$570.80M
1W Performance:
+3.74%
1M Performance:
-13.65%
6M Performance:
-29.05%
1Y Performance:
-19.11%
1-Day Range:
$58.35
$61.15
1-Week Range:
$57.20
$61.15
52-Week Range:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
60.23 | 22.78B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DXCM Announcement: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (DXCM) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit - PR Newswire
Bank Julius Baer & Co. Ltd Zurich Sells 8,697 Shares of DexCom, Inc. $DXCM - Defense World
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
Top 2 Healthcare Stocks Every New Investor Should Know - The Motley Fool
DexCom, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsDXCM - MarketScreener
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
DexCom Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DCXM DEADLINE ALERT: DexCom, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action Lawsuit - GlobeNewswire
Dexcom (DXCM) Valuation: Assessing Upside After FDA Clearance of Smart Basal Diabetes Device - Yahoo Finance Singapore
Levi & Korsinsky Notifies Shareholders of DexCom, Inc. (DXCM) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire
Dexcom Smart Basal Receives FDA Clearance for Personalized Basal Insulin Dosing - Pharmacy Times
DXCM Deadline Alert: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Dexcom to Release G7 15 Day CGM Next Month - Medical Product Outsourcing
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States - GuruFocus
Dexcom G7 15 day continuous glucose monitoring system to launch on Dec. 1 in the United States - MarketScreener
Dexcom G7 15 Day Continuous Glucose Monitoring System To Launch On Dec. 1 In The United States - TradingView
The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025DXCM - PR Newswire
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal - Zacks Investment Research
Is DexCom Inc. (DC4) stock cheap by valuation metricsQuarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
FDA clearances: Dexcom, GE HealthCare, Zimmer Biomet, BrainsWay - Modern Healthcare News
DexCom, Inc. $DXCM Shares Acquired by Artisan Partners Limited Partnership - Defense World
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - MarketScreener
Will DexCom Inc. (DC4) stock profit from AI boomWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Can DexCom Inc. (DC4) stock sustain revenue momentumOil Prices & Long-Term Growth Stock Strategies - newser.com
Bragar Eagel & Squire, P.C. Urges Stockholders of DexCom, - GlobeNewswire
FDA clears Dexcom Smart Basal for insulin optimization - BioWorld MedTech
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM - GlobeNewswire
Why DexCom Inc. stock is in analyst buy zoneJuly 2025 Recap & Capital Efficient Trade Techniques - newser.com
Dexcom Smart Basal wins FDA Clearance for Type 2 diabetes insulin support - Medical Economics
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
FDA OKs Dexcom’s Insulin Dosing Optimizer for Type 2 Diabetes - Medical Product Outsourcing
DexCom Receives US FDA Approval for Insulin Dosing Optimizer - MarketScreener
Will DexCom Inc. (DC4) stock keep high P E multiplesQuarterly Portfolio Report & Real-Time Market Sentiment Reports - newser.com
DexCom (DXCM) Gains FDA Approval for Smart Basal Insulin Dosing Optimizer - GuruFocus
Dexcom Smart Basal Receives FDA Clearance Becoming the First and - GuruFocus
Dexcom receives FDA clearance for first CGM-integrated basal insulin optimizer By Investing.com - Investing.com South Africa
Dexcom wins FDA nod for smart CGM-integrated basal dosing for type 2 diabetes - MassDevice
Dexcom smart basal receives FDA clearance becoming the first and only CGM-integrated basal insulin dosing optimizer for type 2 diabetes - MarketScreener
Dexcom receives FDA clearance for first CGM-integrated basal insulin optimizer - Investing.com Australia
Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes - DexCom Investor Relations
Is DexCom Inc. stock a bargain at current levelsJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com
DexCom Inc. stock outlook for YEAREarnings Recap Report & Fast Entry Momentum Alerts - newser.com
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - NewMediaWire
Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations - Nasdaq
Alberta Investment Management Corp Has $450,000 Position in DexCom, Inc. $DXCM - Defense World
DexCom (DXCM) eyes deeper correction toward $44.11–$20.95 zone - FXStreet
Dexcom Wrongful Death Lawsuit Alleges Continuous Glucose Monitor Failed - AboutLawsuits.com
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
Join Class Action to Recover Losses from DexCom, Inc. (DXCM)Contact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):